For example, FDA approved drugs for the treatment of recurrent GBM, including small molecule inhibitors of the VEGFR kinase and anti-VEGF antibodies like bevacizumab, target the VEGF pathways (Table 1). This evidence concerns the gene VEGFA and glioblastoma.